Cure My Disease

Don't miss your cure!

 Log in / Sign up

Protein clues may predict bladder Cancer's return

NCT ID NCT07657299

Completed Knowledge-focused Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether three proteins (E-cadherin, β-catenin, and SOX4) can help predict if non-muscle invasive bladder cancer will return or get worse after surgery. Researchers examined tissue samples from 30 patients who had bladder tumor removal. The goal was to see if changes in these proteins are linked to cancer recurrence or progression, which could eventually help doctors plan better follow-up care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict which bladder cancers are likely to return or spread, leading to more personalized follow-up care.
What could go wrong
This is a small, retrospective study with only 30 participants. The findings are preliminary and need to be confirmed in larger, prospective trials before they can be used in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma Disease Progression non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms Recurrence urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER BLADDER CANCER RECURRENCE

Contacts and locations

Locations

  • Faculty of medicine, Ain Shams University

    Cairo, Abbasia, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.